Project
Corporate finance
Project
Sun pharmaceuticals
Sun pharmaceuticals
Submitted to :
Prof. S.Ramesh
Submitted by :
Shamili.M (FPB1214/125)
Submitted to :
Prof. S.Ramesh
Submitted by :
Shamili.M (FPB1214/125)
Type | Public | Traded as | BSE : 524715 NSE: sunpharma | Industry | Pharmaceuticals | Founded | 1983 | Founder | Dilip Shanghvi | Headquarters | Mumbai, India. | Key people | Chairman : Israel Makov , MD : Dilip Shanghvi | Products | Pharmaceuticals, Generic drugs | Revenue | INR 8500 crore | Net income | INR 2972 crore | Employees | 11200 | Website | www.sunpharma.com | EXECUTIVE SUMMARY:
Fundamental analysis involves analyzing the underlying forces that affect the well-being of the economy, industry groups, and companies. Most often, the aim of company analysis is to derive a stock's current fair value and forecast future value. If fair value is not equal to the current stock price, fundamental analysts believe that the stock is either over or under valued and the market price will ultimately gravitate towards fair value. By believing that prices do not accurately reflect all available information, fundamental analysts look to capitalize on perceived price discrepancies. In this project an attempt has been made to analyzed financial performance of Sun Pharmaceuticals Industries limited. Earlier part of the report gives information about Indian economy and industry scenario. The later part of the project gives information about company financial performance and ratios analysis. This study will help us to determine the financial health of a company.
Indian Pharmaceutical Industry Overview: The Indian Pharmaceutical Industry today is in the front rank of India’s